The concomitant use of drugs listed below may interfere with the assessment of efficacy, safety, or tolerability of the study medicinal products. Therefore, they are prohibited for the patient at randomization or at any time during the entire study period:
-Inducers of hepatic drug metabolism (rifampin, phenytoin, phenobarbital, carbamazepine) or substrates or inhibitors of CYP2D6 such as amiodarone, cimetidine, fluoxetine, paroxetine, quinidine, amitryptiline, etc.
-Any opioid or opioid containing medication such as morphine, oxycodone, fentanyl, buprenophin, codeine etc. 
